Acer Therapeutics Inc  

(Public, NASDAQ:ACER)   Watch this stock  
Find more results for Opexa
19.29
+0.29 (1.53%)
Jan 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.88 - 19.40
52 week 5.70 - 22.63
Open 19.10
Vol / Avg. 21,603.00/46,838.00
Mkt cap 142.12M
P/E     -
Div/yield     -
EPS -4.03
Shares 7.37M
Beta 2.23
Inst. own 1%
Nov 13, 2017
Q3 2017 Acer Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -274.69%
Operating margin - -275.08%
EBITD margin - -231.13%
Return on average assets -146.90% -92.85%
Return on average equity -170.41% -
Employees 9 -
CDP Score - -

Address

One Gateway Center (300 Washington St.) Suite 351
NEWTON, MA 02458
United States - Map
+1-281-2729331 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Officers and directors

Christopher Schelling President, Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Harry S. Palmin Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
William T. Andrews Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Jason Amello Director
Bio & Compensation  - Reuters
Stephen J. Aselage Director
Bio & Compensation  - Reuters
Hubert Birner Director
Bio & Compensation  - Reuters
John M. Dunn Director
Bio & Compensation  - Reuters
Michelle Griffin Director
Bio & Compensation  - Reuters